核苷(酸)类似物是目前慢性乙型肝炎(CHB) 抗病毒治疗的主要药物。对乙型肝炎病毒(HBV) 耐药机制进行研究，可针对性地为CHB 患者提供个性化耐药防治措施，提高疗效，改善预后。近年来， HBV 耐药机制研究取得了系列进展。本文就近10年来有关CHB治疗中HBV对核苷(酸)类似物耐药机制的研究进展作一综述。

Nucleos(t)ide analogue therapy is currently the main method of antiviral treatment for chronic hepatitis B (CHB). A comprehensive understanding of the resistance mechanisms of hepatitis B virus (HBV) can not only provide CHB patients with personalized drug prevention measures but also improve the efficacy of prognosis. The cunent progress on HBV resistance to nucleos( t) ide analogues has been reviewed in this paper.